Cargando…

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop a vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnusson, Sofia E., Altenburg, Arwen F., Bengtsson, Karin Lövgren, Bosman, Fons, de Vries, Rory D., Rimmelzwaan, Guus F., Stertman, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899102/
https://www.ncbi.nlm.nih.gov/pubmed/29594879
http://dx.doi.org/10.1007/s12026-018-8991-x
_version_ 1783314227562283008
author Magnusson, Sofia E.
Altenburg, Arwen F.
Bengtsson, Karin Lövgren
Bosman, Fons
de Vries, Rory D.
Rimmelzwaan, Guus F.
Stertman, Linda
author_facet Magnusson, Sofia E.
Altenburg, Arwen F.
Bengtsson, Karin Lövgren
Bosman, Fons
de Vries, Rory D.
Rimmelzwaan, Guus F.
Stertman, Linda
author_sort Magnusson, Sofia E.
collection PubMed
description Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop a vaccine that provides broad protection against different influenza A viruses are under investigation, including use of recombinant (r) viral vectors and adjuvants. The replication-deficient modified vaccinia virus Ankara (MVA) is a promising vaccine vector that efficiently induces B and T cell responses specific for the antigen of interest. It is assumed that live vaccine vectors do not require an adjuvant to be immunogenic as the vector already mediates recruitment and activation of immune cells. To address this topic, BALB/c mice were vaccinated with either protein- or rMVA-based HA influenza vaccines, formulated with or without the saponin-based Matrix-M™ adjuvant. Co-formulation with Matrix-M significantly increased HA vaccine immunogenicity, resulting in antigen-specific humoral and cellular immune responses comparable to those induced by unadjuvanted rMVA-HA. Of special interest, rMVA-HA immunogenicity was also enhanced by addition of Matrix-M, demonstrated by enhanced HA inhibition antibody titres and cellular immune responses. Matrix-M added to either protein- or rMVA-based HA vaccines mediated recruitment and activation of antigen-presenting cells and lymphocytes to the draining lymph node 24 and 48 h post-vaccination. Taken together, these results suggest that adjuvants can be used not only with protein-based vaccines but also in combination with rMVA to increase vaccine immunogenicity, which may be a step forward to generate new and more effective influenza vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12026-018-8991-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5899102
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-58991022018-04-17 Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice Magnusson, Sofia E. Altenburg, Arwen F. Bengtsson, Karin Lövgren Bosman, Fons de Vries, Rory D. Rimmelzwaan, Guus F. Stertman, Linda Immunol Res Original Article Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop a vaccine that provides broad protection against different influenza A viruses are under investigation, including use of recombinant (r) viral vectors and adjuvants. The replication-deficient modified vaccinia virus Ankara (MVA) is a promising vaccine vector that efficiently induces B and T cell responses specific for the antigen of interest. It is assumed that live vaccine vectors do not require an adjuvant to be immunogenic as the vector already mediates recruitment and activation of immune cells. To address this topic, BALB/c mice were vaccinated with either protein- or rMVA-based HA influenza vaccines, formulated with or without the saponin-based Matrix-M™ adjuvant. Co-formulation with Matrix-M significantly increased HA vaccine immunogenicity, resulting in antigen-specific humoral and cellular immune responses comparable to those induced by unadjuvanted rMVA-HA. Of special interest, rMVA-HA immunogenicity was also enhanced by addition of Matrix-M, demonstrated by enhanced HA inhibition antibody titres and cellular immune responses. Matrix-M added to either protein- or rMVA-based HA vaccines mediated recruitment and activation of antigen-presenting cells and lymphocytes to the draining lymph node 24 and 48 h post-vaccination. Taken together, these results suggest that adjuvants can be used not only with protein-based vaccines but also in combination with rMVA to increase vaccine immunogenicity, which may be a step forward to generate new and more effective influenza vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12026-018-8991-x) contains supplementary material, which is available to authorized users. Springer US 2018-03-28 2018 /pmc/articles/PMC5899102/ /pubmed/29594879 http://dx.doi.org/10.1007/s12026-018-8991-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Magnusson, Sofia E.
Altenburg, Arwen F.
Bengtsson, Karin Lövgren
Bosman, Fons
de Vries, Rory D.
Rimmelzwaan, Guus F.
Stertman, Linda
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title_full Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title_fullStr Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title_full_unstemmed Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title_short Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
title_sort matrix-m™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus ankara-based influenza vaccines in mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899102/
https://www.ncbi.nlm.nih.gov/pubmed/29594879
http://dx.doi.org/10.1007/s12026-018-8991-x
work_keys_str_mv AT magnussonsofiae matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT altenburgarwenf matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT bengtssonkarinlovgren matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT bosmanfons matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT devriesroryd matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT rimmelzwaanguusf matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice
AT stertmanlinda matrixmadjuvantenhancesimmunogenicityofbothproteinandmodifiedvacciniavirusankarabasedinfluenzavaccinesinmice